37. 膿疱性乾癬（汎発型） Disease details / Clinical trials / Drug dev / DR info

Acitretin
   Department of Dermatology, Children's Hospital of Chongqing Medical University
      2021   Phase 0   ChiCTR2100044690   China
   Institute of dermatology, Chinese Academy of Medical Sciences
      2011   -   ChiCTR-TRC-12003542   China
   Shanghai Dermatology Hospital
      2020   Phase 0   ChiCTR2000037099   China
Adalimumab
   AbbVie
      2015   Phase 3   NCT02533375   Japan
AIN457
   NOVARTIS FARMA S.p.A.
      2014   Phase 3   EUCTR2013-003086-34-IT   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
   Novartis Farmacéutica, S.A.
      2013   Phase 3   EUCTR2013-003086-34-ES   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
   Novartis Pharma K.K.
      2013   Phase 3   JPRN-jRCT2080222256   -
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-003086-34-PL   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2014   Phase 3   EUCTR2013-003086-34-BE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2013   Phase 3   EUCTR2013-003086-34-SE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2013   Phase 3   EUCTR2013-003086-34-GB   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2013   Phase 3   EUCTR2013-003086-34-AT   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
AIN457, 150MG
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2013-003086-34-DE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
Alefacept
   The Guenther Dermatology Research Centre
      2005   Phase 2   NCT00301002   Canada
Alvarez 2
   AnaptysBio Inc.
      2018   Phase 2   EUCTR2017-004021-33-GB   United Kingdom;United States
Anakinra
   Guy's and St Thomas NHS Foundation Trust
      2016   Phase 4   EUCTR2015-003600-23-GB   United Kingdom
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2013   Phase 2   NCT01794117   United States
ANB019
   AnaptysBio Inc.
      2022   Phase 3   EUCTR2021-001448-90-FR   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand
      2022   Phase 3   EUCTR2021-001448-90-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand
      2022   Phase 3   EUCTR2021-001447-27-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand
      2021   Phase 3   EUCTR2021-001448-90-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United States
      2021   Phase 3   EUCTR2021-001447-27-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United States
      2018   Phase 2   EUCTR2017-004021-33-GB   United Kingdom;United States
   AnaptysBio, Inc.
      2019   Phase 2   NCT03619902   Korea, Republic of;Poland;United Kingdom;United States
ANTI-IL-36R monoclonal antibody
   AnaptysBio Inc.
      2022   Phase 3   EUCTR2021-001448-90-FR   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand
      2022   Phase 3   EUCTR2021-001448-90-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand
      2022   Phase 3   EUCTR2021-001447-27-ES   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Spain;Taiwan;Thailand
      2021   Phase 3   EUCTR2021-001448-90-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United States
      2021   Phase 3   EUCTR2021-001447-27-DE   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Poland;Romania;Spain;Taiwan;Thailand;United States
      2018   Phase 2   EUCTR2017-004021-33-GB   United Kingdom;United States
ANY biologic treatment FOR psoriasis
   Bristol-Myers Squibb
      2025   -   NCT06952465   Japan
BI 655130
      2019   Phase 2   EUCTR2017-004231-37-DE   China;France;Germany;Japan;Korea, Republic of;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2020   Phase 2   EUCTR2018-003081-14-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Croatia;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2018-003081-14-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim
      2019   Phase 2   JPRN-jRCT2080224510   Africa;Asia except Japan;Europe;Japan;North America
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2018-003081-14-GR   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2018-003080-56-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim España, S.A.
      2020   Phase 2   EUCTR2018-003081-14-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Croatia;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
   Boehringer Ingelheim France
      2020   Phase 2   EUCTR2018-003081-14-FR   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
      2019   Phase 3   EUCTR2018-003080-56-FR   Australia;Belgium;Bulgaria;China;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Switzerland;Taiwan;Thailand;Tunisia;United States
      2019   Phase 2   EUCTR2017-004231-37-FR   France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States
   Boehringer Ingelheim Netherlands BV
      2020   Phase 2   EUCTR2018-003081-14-NL   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2018-003081-14-DE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam
      2019   Phase 2   EUCTR2018-003080-56-DE   Argentina;Belgium;Bulgaria;Chile;China;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Viet Nam
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2018-003081-14-HR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      2021   Phase 2   EUCTR2018-003081-14-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      2021   Phase 2   EUCTR2018-003080-56-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      -   Phase 2   EUCTR2018-003081-14-CZ   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim SComm
      2022   Phase 2   EUCTR2018-003080-56-BE   Argentina;Belgium;Bulgaria;Chile;China;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Viet Nam
   Ohno Masashi
      2022   -   JPRN-jRCT2071210127   -
   SCS Boehringer Ingelheim Comm. V
      -   Phase 2   EUCTR2018-003081-14-BE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Taguchi Aya
      2021   Phase 2   JPRN-jRCT2041210087   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea;Malaysia;Mexico;Netherlands;Philippines;Poland;Russia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey
BI655130
   Boehringer Ingelheim
      2016   Phase 1   NCT02978690   France;Japan;Korea, Republic of;Malaysia;Singapore;Taiwan;Tunisia
Bimekizumab
   UCB Japan Co., Ltd.
      2018   Phase 3   JPRN-jRCT2080224002   Asia except Japan;Europe;Japan;North America;Oceania
Brodalumab
   Kyowa Hakko Kirin Co., Ltd.
      2014   Phase 3   JPRN-jRCT2080222380   -
      2013   Phase 3   JPRN-jRCT2080222011   -
Brodalumab 210MG SC
   Kyowa Kirin Co., Ltd.
      2016   Phase 4   NCT04183881   Japan
Calcitriol
   Probiodrug AG
      2007   -   EUCTR2006-005344-83-DE   Germany
Certolizumab pegol
   UCB Biopharma S.P.R.L.
      2017   Phase 2/Phase 3   NCT03051217   Japan
CNTO1959
   JANSSEN CILAG INTERNATIONAL NV
      2019   Phase 3   EUCTR2018-003206-58-IT   France;Germany;Italy;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2019   Phase 3   EUCTR2018-003206-58-GB   France;Germany;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-FR   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-ES   France;Germany;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-DE   France;Germany;Italy;Spain;United Kingdom
Deucravacitinib
   Bristol-Myers Squibb
      2025   -   NCT06952465   Japan
Efalizumab
   Technische Universität Dresden
      2007   -   EUCTR2007-003922-70-DE   Germany
Guselkumab
   JANSSEN CILAG INTERNATIONAL NV
      2019   Phase 3   EUCTR2018-003206-58-IT   France;Germany;Italy;Spain;United Kingdom
   Janssen Pharmaceutical K.K.
      2015   Phase 3   NCT02343744   Japan
   Janssen-Cilag International N.V.
      2019   Phase 3   EUCTR2018-003206-58-GB   France;Germany;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-FR   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-ES   France;Germany;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-DE   France;Germany;Italy;Spain;United Kingdom
Guselkumab 100 MG
   Janssen-Cilag Ltd.
      2019   Phase 3   NCT03998683   France;Germany;Italy;Spain;United Kingdom
HB0034
   Shanghai Huaota Biopharmaceutical Co., Ltd.
      2024   Phase 2/Phase 3   NCT06477536   China
      2024   Phase 2   NCT06231381   China
      2022   Phase 1   NCT05512598   China
Imsidolimab
   AnaptysBio, Inc.
      2022   Phase 3   NCT05366855   Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Spain;Taiwan;Thailand;Tunisia;Turkey;United States
   Randazzo Bruce
      2023   Phase 3   JPRN-jRCT2041230033   Australia;China;Georgia;Germany;Japan;Korea;Malaysia;Morocco;Poland;Romania;Slovakia;Spain;Thailand;Tunisia;Turkey;US
Imsidolimab high dose
   AnaptysBio, Inc.
      2022   Phase 3   NCT05352893   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Slovakia;Spain;Taiwan;Thailand;Tunisia;Turkey;United States
Imsidolimab LOW dose
   AnaptysBio, Inc.
      2022   Phase 3   NCT05352893   Australia;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Slovakia;Spain;Taiwan;Thailand;Tunisia;Turkey;United States
Infliximab
   Pfizer
      2019   -   NCT03885089   Japan
   TOYAMA SATOSHI
      2018   -   JPRN-jRCTs031180367   -
   The University of Tokyo Hospital
      2017   -   JPRN-UMIN000027208   Japan
Ixekizumab
   Eli Lilly and Company
      2019   Phase 4   NCT03942042   Japan
JNJ-77242113
   Janssen Pharmaceutical K.K.
      2024   Phase 3   NCT06295692   Japan
KHK4827
   Kyowa Hakko Kirin Co., Ltd.
      2014   Phase 3   JPRN-jRCT2080222380   -
      2013   Phase 3   JPRN-jRCT2080222011   -
   Kyowa Hakko Kirin Company, Limited
      2013   Phase 3   NCT01782937   Japan
KHK4827 140MG SC
   Kyowa Kirin Co., Ltd.
      2014   Phase 3   NCT02052609   Japan
KHK4827 210MG SC
   Kyowa Kirin Co., Ltd.
      2014   Phase 3   NCT02052609   Japan
Melatonin
   Department of Dermatology, Children's Hospital of Chongqing Medical University
      2021   Phase 0   ChiCTR2100044690   China
Mirikizumab
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-jRCT2080224006   Asia except Japan;Europe;Japan;North America;Oceania;South America
Monoclonal antibody ANTI-IGG1
      2019   Phase 2   EUCTR2017-004231-37-DE   China;France;Germany;Japan;Korea, Republic of;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2020   Phase 2   EUCTR2018-003081-14-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Croatia;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2018-003081-14-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2018-003081-14-GR   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2018-003080-56-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim España, S.A.
      2020   Phase 2   EUCTR2018-003081-14-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Croatia;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
   Boehringer Ingelheim France
      2020   Phase 2   EUCTR2018-003081-14-FR   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
      2019   Phase 3   EUCTR2018-003080-56-FR   Australia;Belgium;Bulgaria;China;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;Singapore;Spain;Switzerland;Taiwan;Thailand;Tunisia;United States
      2019   Phase 2   EUCTR2017-004231-37-FR   France;Germany;Japan;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States
   Boehringer Ingelheim Netherlands BV
      2020   Phase 2   EUCTR2018-003081-14-NL   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2018-003081-14-DE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam
      2019   Phase 2   EUCTR2018-003080-56-DE   Argentina;Belgium;Bulgaria;Chile;China;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Viet Nam
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2018-003081-14-HR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      2021   Phase 2   EUCTR2018-003081-14-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      2021   Phase 2   EUCTR2018-003080-56-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      -   Phase 2   EUCTR2018-003081-14-CZ   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim SComm
      2022   Phase 2   EUCTR2018-003080-56-BE   Argentina;Belgium;Bulgaria;Chile;China;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Viet Nam
   SCS Boehringer Ingelheim Comm. V
      -   Phase 2   EUCTR2018-003081-14-BE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
Oxymatrine
   General Hospital of Ningxia Medical University
      2018   Phase 0   ChiCTR2100043193   China
P32/98
   Probiodrug AG
      2007   -   EUCTR2006-005344-83-DE   Germany
Raptiva
   Technische Universität Dresden
      2007   -   EUCTR2007-003922-70-DE   Germany
Risankizumab
   AbbVie
      2017   Phase 3   NCT03022045   Japan
Secukinumab
   Chao Ji
      2019   -   NCT06391996   China
   Eli Lilly Japan K.K.
      2018   Phase 3   JPRN-jRCT2080224006   Asia except Japan;Europe;Japan;North America;Oceania;South America
   NOVARTIS FARMA S.p.A.
      2014   Phase 3   EUCTR2013-003086-34-IT   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
   Novartis Farmacéutica, S.A.
      2013   Phase 3   EUCTR2013-003086-34-ES   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
   Novartis Pharma K.K.
      2013   Phase 3   JPRN-jRCT2080222256   -
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-003086-34-PL   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2013   Phase 3   EUCTR2013-003086-34-SE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2013   Phase 3   EUCTR2013-003086-34-GB   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2013   Phase 3   EUCTR2013-003086-34-DE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
      2013   Phase 3   EUCTR2013-003086-34-AT   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01952015   Japan
Secukinumab 150 MG/1 ML solution FOR injection
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-003086-34-BE   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
Secukinumab 150MG
   Novartis Pharmaceuticals
      2013   Phase 3   NCT02008890   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
Secukinumab 300MG
   Novartis Pharmaceuticals
      2013   Phase 3   NCT02008890   Austria;Belgium;France;Germany;Italy;Poland;Russian Federation;Spain;Sweden;United Kingdom
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2024   Phase 3   ChiCTR2400083906   China
Silikis 3µG/G salbe
   Probiodrug AG
      2007   -   EUCTR2006-005344-83-DE   Germany
Spesolimab
      2019   Phase 2   EUCTR2017-004231-37-DE   China;France;Germany;Japan;Korea, Republic of;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States
   BOEHRINGER-INGELHEIM ITALIA S.P.A.
      2020   Phase 2   EUCTR2018-003081-14-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Croatia;Czech Republic;Czechia;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
   Boehringer Ingelheim RCV GmbH & Co KG
      2020   Phase 2   EUCTR2018-003081-14-PL   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim
      2023   Phase 4   NCT06013969   Australia;Belgium;Brazil;China;France;Germany;India;Italy;Korea, Republic of;Malaysia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United States
      2023   -   NCT05670821   Japan
      2022   Phase 3   NCT05239039   China
      2022   Phase 3   NCT05200247   Japan
      2020   Phase 2   NCT04399837   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czechia;France;Georgia;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
      2020   Phase 2   JPRN-jRCT2080225291   Africa;Asia except Japan;Europe;Japan;North America;Oceania;South America
      2019   Phase 2   NCT03886246   Argentina;Belgium;Chile;China;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
      2019   Phase 2   NCT03782792   China;France;Germany;Japan;Korea, Republic of;Malaysia;Singapore;Switzerland;Taiwan;Thailand;Tunisia;United States
      2019   Phase 2   JPRN-jRCT2080224510   Africa;Asia except Japan;Europe;Japan;North America
   Boehringer Ingelheim BV
      2020   Phase 2   EUCTR2018-003081-14-GR   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2018-003080-56-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim España, S.A.
      2020   Phase 2   EUCTR2018-003081-14-ES   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Croatia;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
   Boehringer Ingelheim France
      2020   Phase 2   EUCTR2018-003081-14-FR   Argentina;Australia;Belgium;Brazil;Chile;China;Czech Republic;Egypt;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Vietnam
   Boehringer Ingelheim Netherlands BV
      2020   Phase 2   EUCTR2018-003081-14-NL   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2020   Phase 2   EUCTR2018-003081-14-DE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Viet Nam
      2019   Phase 2   EUCTR2018-003080-56-DE   Argentina;Belgium;Bulgaria;Chile;China;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Viet Nam
   Boehringer Ingelheim RCV GmbH & Co KG
      2021   Phase 2   EUCTR2018-003081-14-HR   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      2021   Phase 2   EUCTR2018-003081-14-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Latvia;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      2021   Phase 2   EUCTR2018-003080-56-BG   Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;China;Colombia;Croatia;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
      -   Phase 2   EUCTR2018-003081-14-CZ   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Boehringer Ingelheim SComm
      2022   Phase 2   EUCTR2018-003080-56-BE   Argentina;Belgium;Bulgaria;Chile;China;France;Germany;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Philippines;Russian Federation;Spain;Taiwan;Thailand;Tunisia;Turkey;United States;Viet Nam
   Ohno Masashi
      2022   -   JPRN-jRCT2071210127   -
   SCS Boehringer Ingelheim Comm. V
      -   Phase 2   EUCTR2018-003081-14-BE   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Czechia;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Philippines;Poland;Russian Federation;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United States;Vietnam
   Second Affiliated Hospital of Zhejiang University
      2024   Phase 4   ChiCTR2400089387   China
   Taguchi Aya
      2021   Phase 2   JPRN-jRCT2041210087   Argentina;Australia;Belgium;Bulgaria;Chile;China;Colombia;Croatia;Czech Republic;Egypt;France;Georgia;Germany;Greece;Israel;Italy;Japan;Korea;Malaysia;Mexico;Netherlands;Philippines;Poland;Russia;Singapore;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey
TA-650
   Mitsubishi Tanabe Pharma Corporation
      2012   Phase 3   NCT01680159   Japan
TAK-279
   Takeda
      2024   Phase 3   NCT06323356   Japan
TQH2929 injection
   Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
      2024   Phase 1   NCT06433531   China
Tremfya
   JANSSEN CILAG INTERNATIONAL NV
      2019   Phase 3   EUCTR2018-003206-58-IT   France;Germany;Italy;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2019   Phase 3   EUCTR2018-003206-58-GB   France;Germany;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-FR   France;Germany;Italy;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-ES   France;Germany;Spain;United Kingdom
      2019   Phase 3   EUCTR2018-003206-58-DE   France;Germany;Italy;Spain;United Kingdom
Ustekinumab
   Chao Ji
      2019   -   NCT06391996   China
   Innovaderm Research Inc.
      2010   Phase 3   NCT01091051   Canada